Anti-progestins suppress the growth of established tumors induced by 7,12-dimethylbenz(a)anthracene: Comparison between RU486 and a new 21-substituted-19-nor-progestin

Oncology Reports

Volumn 18, Issue 1, 2007, Pages 167-174

  Wiehle, Ronald D ^a   Christov, Konstantin ^b   Mehta, Rajendra ^c  

^a Repros Therapeutics Inc   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c IIT RESEARCH INSTITUTE   (United States)

Author keywords

Anti progestins; Apoptosis; Carcinogenesis; CDB 4124; Progesterone; Proliferation; RU486

Indexed keywords

17ALPHA ACETOXY 11BETA (4 DIMETHYLAMINOPHENYL) 21 METHOXY 19 NORPREGNA 4,9 DIENE 3,20 DIONE; 7,12 DIMETHYLBENZ[A]ANTHRACENE; CARCINOGEN; CDB-4124; GESTAGEN; HORMONE ANTAGONIST; MIFEPRISTONE; PREGNANE DERIVATIVE; PROGESTERONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHEMICALLY INDUCED DISORDER; CHEMISTRY; COMPARATIVE STUDY; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; APOPTOSIS; CARCINOGENS; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; HORMONE ANTAGONISTS; MAMMARY NEOPLASMS, EXPERIMENTAL; MIFEPRISTONE; NORPREGNADIENES; PROGESTERONE CONGENERS; PROGESTINS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 34548044259     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.1.167     Document Type: Article

References (33)

1. Clarke CL and Sutherland RL: Progestin regulation of cellular proliferation. Endocrine Rev 11: 266-301, 1990. (Pubitemid 20182871)
2. Longacre TC and Barto SA: A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 10: 382-393, 1986.
3. Going JJ, Anderson TJ, Battersby S and Macintyre CCA: Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol 130: 193-204, 1988. (Pubitemid 18044847)
4. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA and Haslam SZ: Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 84: 4559-4565, 1999.
5. Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333, 2002. (Pubitemid 34761611)
6. Chlebowski RT, Hendrix SL, Langer RD, et al: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289: 3243-3253, 2003. (Pubitemid 37430077)
7. Stefanick ML, Anderson GL, Margolis KL, et al: Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295: 1647-1657, 2006.
8. Pike MC: The role of mammographic density in evaluating changes in breast cancer risk. Gynecol Endocrinol 21 (Suppl 1): 1-5, 2005.
9. Frank DW, Kitron KT, Murchism TE, et al: Mammary tumors and serum hormones in the bitch treated with medroxy-progesterone acetate or progesterone for four years. Fertil Steril 31: 340-346, 1979. (Pubitemid 9125400)
10. Nagasawa H, Aoki M, Sakagami N and Ishida M: Medroxyprogesterone acetate enhances spontaneous mammary tumorigenesis and uterine adenomyosis in mice. Breast Cancer Res Treat 12: 59-66, 1988.
11. Huggins C and Yang NC: Induction and extinction of mammary cancer. A striking effect of hydrocarbons permits analysis of mechanisms of causes and cure of breast cancer. Science 137: 257-261, 1962.
12. Huggins C, Moon RC and Morii S: Extinction of experimental mammary cancer. I. Estradiol-17beta and progesterone. Proc Natl Acad Sci USA 48: 379-385, 1962.
13. Bakker GH, Setyono-Han B, Henkelman MS, et al: Comparison of the actions of the anti-progestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors. Cancer Treat Rep 71: 1021-1027, 1987. (Pubitemid 18002209)
14. Bakker GH, Setyono-Han B, Portengen H, De Jong FH, Foekens JA and Klijn JGM: Treatment of breast cancer with different anti-progestins: preclinical and clinical studies. J Steroid Biochem Mol Biol 37: 789-794, 1990.
15. Attardi B, Burgenson J, Hild S, Reel JR and Blye RP: CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent anti-progestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol 188: 111-123, 2002. (Pubitemid 34242671)
16. Christov, K., Ikui A, Shilkaitis, A, et al: Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors. Breast Cancer Res Treat 77: 253-264, 2003. (Pubitemid 36197640)
17. Kloosterboer HJ, Deckers GH, Schoonen WGEJ, et al: Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids 65: 733-740, 2000.
18. Schneider MR, Michna H, Nishino Y, Neef G and el Etreby MF: Tumor-inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive, experimental rodent and human mammary tumors. Anticancer Res 10: 683-687, 1990. (Pubitemid 20237817)
19. Michna H, Schneider MR, Nishino Y and Etreby MF: Antitumor activity of the anti-progestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies. Breast Cancer Res Treat 14: 275-288, 1989. (Pubitemid 20053757)
20. Robinson SP and Jordan VC: Reversal of the antitumor effects of tamoxifen by progesterone in the 7,12-dimethyl-benzanthracene-induced rat mammary carcinoma model. Cancer Res 47: 5386-5390, 1987. (Pubitemid 17152950)
21. Bakker GH, Setyono-Han B, Portengen H, De Jong FH, Foekens JA and Klijn JGM: Endocrine and antitumor effects of combined treatment with an anti-progestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors. Endocrinology 125: 1593-1598, 1989. (Pubitemid 19224015)
22. Nichino Y, Schneider MR and Mincha H: Enhancement of the antitumor efficacy of the anti-progestin, onapristone, by combination with the antiestrogen, ICI 164384. J Cancer Res Clin Oncol 120: 298-302, 1994. (Pubitemid 24067643)
23. Lydon JP, Ge G, Kitrell FS, Medina D and O'Malley BW: Endocrine and antitumor effects of combined treatment with an anti-progestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors. Cancer Res 59: 4276-4284, 1999.
24. Chatterton RT, Lydon JP, Mehta RG, Mateo ET, Pletz A and Jordan VC: Role of the progesterone receptor (PR) in susceptibility of mouse mammary gland to 7,12-dimethylbenz[a]anthracene-induced hormone-independent preneoplastic lesions in vitro. Cancer Lett 188: 47-52, 2002. (Pubitemid 35292328)
25. Romieu G, Mandelonde T, Ulmann A, et al: The anti-progestin RU486 in advanced breast cancer: preliminary clinical trial. Bull Cancer 74: 455-459, 1987.
26. Klijn JGM, de Jong FH, Bakker GH, Lamberts SWJ, Rodenburg CJ and Alexieva-Figusch J: Anti-progestins: a new form endocrine therapy for breast cancer. Cancer Res 49: 2851-2856, 1989. (Pubitemid 19148614)
27. Perrault D, Eisenhauer EA, Pritchard KL, et al: Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 14: 2709-2712, 1996. (Pubitemid 26329656)
28. Kettel LM, Murphy AA, Mortola AJ, Liu JH, Ulmann A and Yen SSC: Endocrine responses to long-term administration of the anti-progesterone RU486 in patients with pelvic endometriosis. Fertil Steril 56: 402-407, 1991.
29. Liu JH, Garzo G, Morris S, Stuenkel C, Ulmann A and Yen SSC: Disruption of follicular maturation and delay of ovulation after administration of the anti-progesterone RU486. J Clin Endocrinol Metab 65: 1135-1140, 1987. (Pubitemid 18026847)
30. Michna H, Schneider MR, Nishino Y and Etreby MF: The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death. J Steroid Biochem 34: 447-553, 1989.
31. Forby B and Wiley TS: Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53. Ann Clin Lab Sci 28: 360-369, 1998.
32. Bardon S, Vignon F, Montcourrier P and Rochefort H: Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res 47: 1441-1448, 1987. (Pubitemid 17023221)
33. Poole AJ, Li Y, Kim Y, Lin S-CJ, Lee W-H and Lee EY-H: Prevention of Brca-1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314: 1467-1470, 2006. (Pubitemid 44871955)